EP0690849A1 - Derives d'amidine contenant des heterocycles, leur preparation et leur utilisation - Google Patents
Derives d'amidine contenant des heterocycles, leur preparation et leur utilisationInfo
- Publication number
- EP0690849A1 EP0690849A1 EP94911191A EP94911191A EP0690849A1 EP 0690849 A1 EP0690849 A1 EP 0690849A1 EP 94911191 A EP94911191 A EP 94911191A EP 94911191 A EP94911191 A EP 94911191A EP 0690849 A1 EP0690849 A1 EP 0690849A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- alkyl
- formula
- alkoxy
- compounds
- phenyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/84—Sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
- C07D235/12—Radicals substituted by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
- C07D235/26—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/95—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in positions 2 and 4
- C07D239/96—Two oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D253/00—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00
- C07D253/08—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00 condensed with carbocyclic rings or ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D263/32—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D263/34—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D263/36—One oxygen atom
- C07D263/38—One oxygen atom attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D263/34—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D263/46—Sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
- C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
- C07D263/58—Benzoxazoles; Hydrogenated benzoxazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D265/04—1,3-Oxazines; Hydrogenated 1,3-oxazines
- C07D265/12—1,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
- C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
- C07D271/10—1,3,4-Oxadiazoles; Hydrogenated 1,3,4-oxadiazoles
- C07D271/113—1,3,4-Oxadiazoles; Hydrogenated 1,3,4-oxadiazoles with oxygen, sulfur or nitrogen atoms, directly attached to ring carbon atoms, the nitrogen atoms not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/08—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D277/12—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/16—Sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/34—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/36—Sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/38—Nitrogen atoms
- C07D277/42—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
- C07D277/62—Benzothiazoles
- C07D277/68—Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
- C07D277/62—Benzothiazoles
- C07D277/68—Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
- C07D277/70—Sulfur atoms
- C07D277/74—Sulfur atoms substituted by carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
- C07D285/01—Five-membered rings
- C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
- C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
- C07D285/12—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles
- C07D285/125—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles with oxygen, sulfur or nitrogen atoms, directly attached to ring carbon atoms, the nitrogen atoms not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
- C07D285/01—Five-membered rings
- C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
- C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
- C07D285/12—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles
- C07D285/125—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles with oxygen, sulfur or nitrogen atoms, directly attached to ring carbon atoms, the nitrogen atoms not forming part of a nitro radical
- C07D285/13—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
Definitions
- the invention relates to new, heterocycle-containing amidine derivatives, their preparation by conventional methods and their use as active ingredients in
- a 1 is a straight-chain or branched double-bonded aliphatic C 2 -C 6 group, which can also contain a double or triple bond, or one of the groups
- X 1 for O, S, SO, SO 2 , CH 2 , NH or
- Chiral compounds of the formula I can be in the form of racemates, in enantiomerically pure or enriched form and in each case as a base or as salts with inorganic or organic, in particular physiologically
- R 1 and R 2 which are the same or different
- C 1 -C 4 alkyl can be substituted for halogen, OH, CF 3 , R 5 , OR 6 , COR 6 ,
- R 5 represents a heterocyclic five-membered ring with 1 to 3 heteroatoms and the formula
- D, E and G which may be the same or different, are CH, N, C- (C 1 -C 4 alkyl) or
- C is phenyl and L is Ooer S
- R 4 for H, halogen, NH 2 , NH- (C 1 -C 4 alkyl), C 1 -C 4 alkyl, N (C 1 -C 4 alkyl) 2 , OH, C 1 -C 4 - Alkoxy, phenyl,
- R 5 is H, C 1 -C 12 alkyl, pydridyl, phenyl, optionally by halogen, C 1 -C 4 alkyl, C 1 -C 4 alkoxy
- R 6 for C 1 -C 12 alkyl, phenyl or optionally
- R 7 is H or C 1 -C 12 alkyl
- R 8 , R 9 (which may be the same or different)
- R 10 is H or C 1 -C 4 alkyl
- R 11 , R 12 which can be the same or different
- R 13 , R 14 which may be the same or different,
- radicals from the group fluorine, chlorine, bromine, C 1 -C 4 alkyl, C 1 -C 4 alkoxy or pseudohalogens such as CN, CF 3 may be substituted, or for pyridyl.
- a 1 contains a double or triple bond, this is generally not a hetero atom
- R 3 generally means hydrogen only if at least one of the radicals R 1 , R 2 is not hydrogen.
- a 1 ' (CH 2 ) 2-6 , CH 2 -C 6 H 4 -CH 2 ,
- CH 2 -C C-CH 2 ;
- X 1 ' O, S;
- Het ' a group of the above formulas a, b, e, f, g, k, n, where R 1 , R 2 , R 3 , the may be the same or different, mean H, R 5 , OR 5 or COR 5 and
- R 1 and R 2 together also one
- condensed ring can mean.
- Ammonia in an alcohol such as methanol, ethanol, n-propanol, i-propanol, or in an inert solvent, such as dichloromethane,
- Tetrahydrofuran, dioxane at temperatures between about 0 and 50 ° C, preferably at about 20 ° C. 2. Reduction of an amidoxime of the formula
- Het, R 4 , A and B have the above meaning
- a catalyst such as Raney nickel, palladium or platinum.
- O or S can also be according to the scheme
- Metal hydroxides, metal hydrides at temperatures between about 0 and 140 ° C or the boiling point of the reaction mixture.
- the phenols or thiophenols can also be used in the form of salts, for example the alkali salts.
- Suitable as a nucleofugic leaving group eg halogens, such as Br, Cl or residues of
- Sulfonic acids such as methanesulfonic acid
- the starting materials X and XI are preferably from the corresponding nitriles of the formula
- the further synthetic route consists in the reaction of the corresponding nitriles with HCl via the stage of the imide chlorides or the direct reaction with eg
- reaction can also be carried out with a trialkyloxonium salt such as
- nitriles XVI can be reacted with hydroxylamine in alcohols, for example methanol, ethanol, Propanol, isopropanol, the corresponding amidoximes of the formula XI obtained.
- the starting materials of the formulas XII, XIII, XIV and XV can also be prepared by conventional processes.
- the compounds according to the invention can be used therapeutically, in particular because of their
- LTB 4 -antagonistic effect are therefore particularly suitable for use in those diseases in which inflammatory and / or allergic processes play a role, for example IBD (inflammatory bowel diseases), allergic rhinitis; ARDS (adult respiratory distress syndron), asthma, colitis
- IBD inflammatory bowel diseases
- ARDS adult respiratory distress syndron
- asthma chronic respiratory distress syndron
- ulcerative pain, psoriasis also used to treat gastropathy induced by nonsteroidal anti-inflammatory drugs (NSAID).
- NSAID nonsteroidal anti-inflammatory drugs
- the new compounds can also be used in combination with other active ingredients, e.g. B. with antiallergics, secretolytics,
- Antihistamines and / or PAF antagonists are included in the composition.
- Administration can be topical, oral, transdermal, nasal, parenteral or inhalative.
- the therapeutic or prophylactic dose is - apart from the potency of the individual compounds and the body weight of the patient - dependent on the nature and seriousness of the
- the new compounds can be administered topically, orally,
- compositions consisting essentially of an inert pharmaceutical carrier and a
- an effective dose of the active ingredient e.g. Tablets, coated tablets, capsules, wafers, powders, solutions, suspensions, inhalation aerosols, ointments, emulsions, syrups, suppositories, etc.
- An effective dose of the compounds according to the invention is oral
- Inhalation should be used in powders or solutions containing 0.5% to 5% active ingredient, with each dose containing approximately 2 to 20 mg active ingredient.
- the new compounds can be combined, inter alia, with antiallergics, secretolytics, ⁇ 2 -adrenergics, inhalable steroids or antihistamines.
- Active ingredient according to the invention 20 parts by weight
- the ingredients are processed in the usual way to tablets of 500 mg weight.
- the active ingredient content can be increased or decreased and the amount of glucose reduced or increased accordingly.
- Active ingredient according to the invention 100 parts by weight
- the ingredients are processed in the usual way into suppositories weighing 1.7 g.
- Micronized active ingredient powder (compound of formula I; particle size approx. 0.5 to 7 ⁇ m) is added in an amount of 5 mg, optionally with the addition of micronized lactose
- Bottled hard gelatin capsules The powder is inhaled from conventional inhalation devices, for example according to DE-A 3 345 722.
- the compounds of the invention were examined, inter alia, for their action in the tests below. a) LTB 4 receptor connection test
- U937 cells differentiated, human monocytic cell line with naturally expressed
- Concentration of the test substance is dose-dependent inhibited (incubation 2 h at 0 ° C).
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Immunology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
On peut préparer par des procédés classiques des composés ayant la formule (I), dont la signification est expliquée plus en détail dans la description, et les utiliser dans des compositions galéniques thérapeutiques.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE4309285A DE4309285A1 (de) | 1993-03-23 | 1993-03-23 | Heterocyclen enthaltende Amidinderivate, ihre Herstellung und Verwendung |
DE4309285 | 1993-03-23 | ||
PCT/EP1994/000856 WO1994021616A1 (fr) | 1993-03-23 | 1994-03-18 | Derives d'amidine contenant des heterocycles, leur preparation et leur utilisation |
Publications (1)
Publication Number | Publication Date |
---|---|
EP0690849A1 true EP0690849A1 (fr) | 1996-01-10 |
Family
ID=6483550
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP94911191A Ceased EP0690849A1 (fr) | 1993-03-23 | 1994-03-18 | Derives d'amidine contenant des heterocycles, leur preparation et leur utilisation |
Country Status (18)
Country | Link |
---|---|
EP (1) | EP0690849A1 (fr) |
JP (1) | JPH08508467A (fr) |
KR (1) | KR960701026A (fr) |
CN (1) | CN1124486A (fr) |
AU (1) | AU6378094A (fr) |
BG (1) | BG100069A (fr) |
CA (1) | CA2158994A1 (fr) |
CZ (1) | CZ246695A3 (fr) |
DE (1) | DE4309285A1 (fr) |
FI (1) | FI954491A (fr) |
HU (1) | HUT73968A (fr) |
IL (1) | IL109073A0 (fr) |
LV (1) | LV11465B (fr) |
NO (1) | NO953763L (fr) |
PL (1) | PL310806A1 (fr) |
SK (1) | SK117495A3 (fr) |
WO (1) | WO1994021616A1 (fr) |
ZA (1) | ZA941993B (fr) |
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11891366B1 (en) | 2023-10-12 | 2024-02-06 | King Faisal University | 4-methoxy-n′-(2-(5-phenyl-1,3,4-oxadiazol-2-ylthio)acetoxy)benzimidamide as an antimicrobial compound |
US11897850B1 (en) | 2023-10-11 | 2024-02-13 | King Faisal University | N′-(2-(5-(4-chlorophenyl)-1,3,4-oxadiazol-2-ylthio)acetoxy)-4-methoxybenzimidamide as an antimicrobial compound |
US11905263B1 (en) | 2023-10-13 | 2024-02-20 | King Faisal University | 4-nitro-N′-(2-(5-phenyl-1,3,4-oxadiazol-2-ylthio)acetoxy)benzimidamide as an antimicrobial compound |
US11912675B1 (en) | 2023-10-11 | 2024-02-27 | King Faisal University | N'-(2-(5-(4-chlorophenyl)-1,3,4-oxadiazol-2-ylthio)acetoxy)-3,4-dimethoxybenzimidamide as an antimicrobial compound |
US11919872B1 (en) | 2023-10-11 | 2024-03-05 | King Faisal University | N′-(2-(5-(4-chlorophenyl)-1,3,4-oxadiazol-2-ylthio)acetoxy)benzimidamide as an antimicrobial compound |
US11932632B1 (en) | 2023-10-13 | 2024-03-19 | King Faisal University | N'-(2-(5-phenyl-1,3,4-oxadiazol-2-ylthio)acetoxy)benzo[d][1,3]dioxole-5 carboximidamide as an antimicrobial compound |
US11976050B1 (en) | 2023-10-11 | 2024-05-07 | King Faisal University | N′-(2-(5-(4-chlorophenyl)-1,3,4-oxadiazol-2-ylthio)acetoxy)-1-naphthimidamide as an antimicrobial compound |
US11999706B1 (en) | 2023-10-13 | 2024-06-04 | King Faisal University | 4-chloro-N′-(2-(5-(4-chlorophenyl)-1,3,4-oxadiazol-2-ylthio)acetoxy)benzimidamide as an antimicrobial compound |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE19546452A1 (de) * | 1995-12-13 | 1997-06-19 | Boehringer Ingelheim Kg | Neue Phenylamidinderivate, Verfahren zu ihrer Herstelung und ihre Verwendung als Arzneimittel |
ID24720A (id) | 1997-12-12 | 2000-08-03 | Novartis Ag | Senyawa amidino tersubstitusi dalam perawatan penyakit gangguan paru-paru kronis |
KR100682199B1 (ko) * | 2004-07-05 | 2007-02-12 | 동화약품공업주식회사 | 알러지성 염증 질환의 예방 및 치료용 조성물 |
KR20060017929A (ko) | 2004-08-04 | 2006-02-28 | 동화약품공업주식회사 | 티아졸 유도체가 치환된 신규한 벤즈아미딘 유도체, 그의제조방법 및 이를 유효성분으로 하는 약학 조성물 |
BRPI0620292B1 (pt) | 2005-12-21 | 2021-08-24 | Janssen Pharmaceutica N. V. | Compostos de triazolopiridazinas como moduladores da cinase, composição, uso, combinação e processo de preparo do referido composto |
WO2008021781A1 (fr) | 2006-08-07 | 2008-02-21 | Incyte Corporation | Utilisation de triazolotriazines en tant qu'inhibiteurs des kinases |
AU2007323725B2 (en) | 2006-11-22 | 2014-02-20 | Incyte Holdings Corporation | Imidazotriazines and imidazopyrimidines as kinase inhibitors |
MY187131A (en) | 2008-05-21 | 2021-09-02 | Incyte Corp | Salts of 2-fluoro-n-methyl-4-[7-(quinolin-6-yl-methyl)-imidazo[1,2-b][1,2,4]triazin-2-yl]benzamide and processes related to preparing the same |
US8487096B2 (en) | 2010-02-03 | 2013-07-16 | Incyte Corporation | Imidazo[1,2-B][1,2,4]triazines as C-MET inhibitors |
KR101216274B1 (ko) * | 2011-06-17 | 2012-12-28 | 이화여자대학교 산학협력단 | 골다공증 완화, 예방 또는 치료효과의 신규한 화합물, 이의 제조방법 및 이를 포함하는 약학조성물 |
WO2013043744A2 (fr) | 2011-09-21 | 2013-03-28 | Inception 1, Inc. | Composés tricycliques utiles comme agents neurogènes et neuroprotecteurs |
CN102993109A (zh) * | 2012-12-03 | 2013-03-27 | 浙江工业大学 | 一种脒化合物的制备方法 |
WO2023144450A1 (fr) * | 2022-01-28 | 2023-08-03 | Oulun Yliopisto | Composés destinés à être utilisés dans le traitement du cancer et d'états inflammatoires |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB868552A (en) * | 1957-12-03 | 1961-05-17 | Wellcome Found | Improvements in or relating to novel amidines and the preparation thereof |
JPS60130561A (ja) * | 1983-12-16 | 1985-07-12 | Torii Yakuhin Kk | アミジン誘導体およびそれを含む強心剤 |
US4889871A (en) * | 1987-05-29 | 1989-12-26 | G. D. Searle & Co. | Alkoxy-substituted dihydrobenzopyran-2-carboxylate derivatives |
EP0518818A3 (en) * | 1991-06-11 | 1993-04-28 | Ciba-Geigy Ag | Arylethers, their manufacture and use as medicament |
ATE125791T1 (de) * | 1991-06-11 | 1995-08-15 | Ciba Geigy Ag | Amidino-verbindungen, ihre herstellung und verwendung als arzneimittel. |
AU2915892A (en) * | 1991-11-14 | 1993-06-15 | Glaxo Group Limited | Piperidine acetic acid derivatives as inhibitors of fibrinogen-dependent blood platelet aggregation |
AU673343B2 (en) * | 1992-02-05 | 1996-11-07 | Boehringer Ingelheim International Gmbh | Novel amidine derivatives, their preparation and their use as mediaments with LTB4 antagonistic effect |
-
1993
- 1993-03-23 DE DE4309285A patent/DE4309285A1/de not_active Withdrawn
-
1994
- 1994-03-18 CZ CZ952466A patent/CZ246695A3/cs unknown
- 1994-03-18 PL PL94310806A patent/PL310806A1/xx unknown
- 1994-03-18 SK SK1174-95A patent/SK117495A3/sk unknown
- 1994-03-18 CN CN94192207A patent/CN1124486A/zh active Pending
- 1994-03-18 WO PCT/EP1994/000856 patent/WO1994021616A1/fr not_active Application Discontinuation
- 1994-03-18 AU AU63780/94A patent/AU6378094A/en not_active Abandoned
- 1994-03-18 JP JP6520657A patent/JPH08508467A/ja active Pending
- 1994-03-18 EP EP94911191A patent/EP0690849A1/fr not_active Ceased
- 1994-03-18 HU HU9502778A patent/HUT73968A/hu unknown
- 1994-03-18 CA CA002158994A patent/CA2158994A1/fr not_active Abandoned
- 1994-03-22 ZA ZA941993A patent/ZA941993B/xx unknown
- 1994-03-22 IL IL10907394A patent/IL109073A0/xx unknown
-
1995
- 1995-09-21 KR KR1019950704014A patent/KR960701026A/ko not_active Application Discontinuation
- 1995-09-22 FI FI954491A patent/FI954491A/fi not_active Application Discontinuation
- 1995-09-22 NO NO953763A patent/NO953763L/no unknown
- 1995-09-22 LV LVP-95-291A patent/LV11465B/lv unknown
- 1995-10-17 BG BG100069A patent/BG100069A/xx unknown
Non-Patent Citations (1)
Title |
---|
See references of WO9421616A1 * |
Cited By (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11897850B1 (en) | 2023-10-11 | 2024-02-13 | King Faisal University | N′-(2-(5-(4-chlorophenyl)-1,3,4-oxadiazol-2-ylthio)acetoxy)-4-methoxybenzimidamide as an antimicrobial compound |
US11912675B1 (en) | 2023-10-11 | 2024-02-27 | King Faisal University | N'-(2-(5-(4-chlorophenyl)-1,3,4-oxadiazol-2-ylthio)acetoxy)-3,4-dimethoxybenzimidamide as an antimicrobial compound |
US11919872B1 (en) | 2023-10-11 | 2024-03-05 | King Faisal University | N′-(2-(5-(4-chlorophenyl)-1,3,4-oxadiazol-2-ylthio)acetoxy)benzimidamide as an antimicrobial compound |
US11976050B1 (en) | 2023-10-11 | 2024-05-07 | King Faisal University | N′-(2-(5-(4-chlorophenyl)-1,3,4-oxadiazol-2-ylthio)acetoxy)-1-naphthimidamide as an antimicrobial compound |
US11999707B1 (en) | 2023-10-11 | 2024-06-04 | King Faisal University | N′-(2-(5-(4-chlorophenyl)-1,3,4-oxadiazol-2-ylthio)acetoxy)-1-naphthimidamide as an antimicrobial compound |
US11891366B1 (en) | 2023-10-12 | 2024-02-06 | King Faisal University | 4-methoxy-n′-(2-(5-phenyl-1,3,4-oxadiazol-2-ylthio)acetoxy)benzimidamide as an antimicrobial compound |
US11905263B1 (en) | 2023-10-13 | 2024-02-20 | King Faisal University | 4-nitro-N′-(2-(5-phenyl-1,3,4-oxadiazol-2-ylthio)acetoxy)benzimidamide as an antimicrobial compound |
US11932632B1 (en) | 2023-10-13 | 2024-03-19 | King Faisal University | N'-(2-(5-phenyl-1,3,4-oxadiazol-2-ylthio)acetoxy)benzo[d][1,3]dioxole-5 carboximidamide as an antimicrobial compound |
US11999706B1 (en) | 2023-10-13 | 2024-06-04 | King Faisal University | 4-chloro-N′-(2-(5-(4-chlorophenyl)-1,3,4-oxadiazol-2-ylthio)acetoxy)benzimidamide as an antimicrobial compound |
US11999705B1 (en) | 2023-10-13 | 2024-06-04 | King Faisal University | 4-chloro-N′-(2-(5-(4-chlorophenyl)-1,3,4-oxadiazol-2-ylthio)acetoxy)benzimidamide as an antimicrobial compound |
US12012388B1 (en) | 2023-10-13 | 2024-06-18 | King Faisal University | 4-chloro-n'-(2-(5-(4-chlorophenyl)-1,3,4-oxadiazol-2-ylthio)acetoxy)benzimidamide as an antimicrobial compound |
Also Published As
Publication number | Publication date |
---|---|
JPH08508467A (ja) | 1996-09-10 |
NO953763L (no) | 1995-09-25 |
KR960701026A (ko) | 1996-02-24 |
SK117495A3 (en) | 1996-01-10 |
LV11465B (en) | 1996-12-20 |
CA2158994A1 (fr) | 1994-09-29 |
HU9502778D0 (en) | 1995-11-28 |
FI954491A0 (fi) | 1995-09-22 |
CN1124486A (zh) | 1996-06-12 |
CZ246695A3 (en) | 1996-02-14 |
IL109073A0 (en) | 1994-06-24 |
HUT73968A (en) | 1996-10-28 |
PL310806A1 (en) | 1996-01-08 |
BG100069A (en) | 1996-04-30 |
WO1994021616A1 (fr) | 1994-09-29 |
NO953763D0 (no) | 1995-09-22 |
DE4309285A1 (de) | 1994-09-29 |
FI954491A (fi) | 1995-09-22 |
LV11465A (lv) | 1996-08-20 |
ZA941993B (en) | 1994-09-23 |
AU6378094A (en) | 1994-10-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP0690849A1 (fr) | Derives d'amidine contenant des heterocycles, leur preparation et leur utilisation | |
EP0902013B1 (fr) | Nouveau dérivés de l'amidine, leur fabrication et leur application en tant que médicaments ayant un effet antagoniste à LTB4 | |
EP0163965B1 (fr) | Pyridazinones, leur préparation et leur utilisation, médicaments contenant des pyridazinones | |
DE2833140C2 (fr) | ||
DE10058310A1 (de) | 2-(3,5-Bistrifluormethylphenyl)-N-methyl-N-(6- morpholin-4-yl-4-o-tolylpyridin -3-yl ) isobutyramid | |
US4029815A (en) | Anti-diarrheal anthranilic acids | |
EP1015421B1 (fr) | Nouveaux derives de phenylamidine, leur procede de preparation et leur utilisation comme medicaments | |
DE3810848A1 (de) | Neue 2,3,4-substituierte imidazole und 3,4,5-substituierte 1,2,4-triazole, ihre herstellung und verwendung | |
DE2344833A1 (de) | Guanidine, ihre salze, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel | |
DE2702537A1 (de) | Neue piperazinderivate, verfahren zu ihrer herstellung und diese enthaltende arzneimittel | |
DE3216843C2 (de) | 3-Thiomethyl-pyridin-Derivate, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel | |
JPS5846089A (ja) | ヘテロ環状化合物 | |
DE2144568A1 (de) | Neue Derivate der Phenyl-5-pyrazolcarbonsäuren-3, Verfahren zu ihrer Herstellung und ihre Verwendung | |
DE1008737B (de) | Verfahren zur Herstellung von Phenthiazinderivaten | |
DE3605676C2 (de) | Ergolinderivate und deren Säureadditionssalze und deren Verwendung | |
DE3134945A1 (de) | Substituierte 2-amino-3,4-dihydropyridinderivate, verfahren zu ihrer herstellung und ihre verwendung in arzneimittel | |
DE2901180A1 (de) | Hexahydro-1,4-oxazepine, verfahren zu deren herstellung und diese enthaltende arzneimittel | |
DE3639466A1 (de) | Neue pyrrolo-benzimidazole, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung | |
DE10052333A1 (de) | Neue Sulfooxybenzamide | |
DE4244241A1 (de) | Neue Verbindungen, ihre Herstellung und ihre Verwendung | |
DE2656227A1 (de) | Basisch alkylierte dithiosalicylsaeureamide, verfahren zu ihrer herstellung sowie ihre verwendung als arzneimittel | |
DE3237438C2 (de) | 2-Thiazolamin-Derivate und dieselben enthaltende pharmazeutische Zusammensetzungen | |
AT325053B (de) | Verfahren zur herstellung von neuen tetrahydropyrimidinen, imidazolinen und tetrahydro-1,3-diazepinen und deren saureadditionssalzen | |
DE4203201A1 (de) | Neue amidinderivate, ihre herstellung und verwendung | |
CH495960A (de) | Verfahren zur Herstellung von neuen Guanylhydrazonen |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 19951023 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE |
|
17Q | First examination report despatched |
Effective date: 19960607 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION HAS BEEN REFUSED |
|
18R | Application refused |
Effective date: 19980101 |